BioSpace News Archive

Applied DNA Sciences, Inc., a leader in PCR-based DNA technologies, announced that its CertainT® supply chain traceability platform is featured in an article on the home page of the New York Times website.

The monoclonal antibodies daratumumab, and elotuzumab have been approved by the U.S. Food and Drug Administration for treating multiple myeloma in 2015.

A regulatory class of human T cells descends from two different origins, one that relates to autoimmunity and one that relates to protective immunity, according to a new study led by Children’s Hospital of Philadelphia.

Assertio Holdings, Inc. announced that effective April 3, 2023, the Compensation Committee of the Company’s Board of Directors granted two newly-hired employees a total of 20,542 restricted stock units and 24,018 stock options.

Calyxt, Inc. (Nasdaq: CLXT) (“Calyxt” or the “Company”) today announced that it will proceed with the 1-for-10 reverse stock split previously approved by the Company’s shareholders at the annual meeting of shareholders on June 1, 2022.

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

Molecular Templates, Inc., announced that the U.S. Food and Drug Administration informed MTEM that it has placed a partial clinical hold on the Phase 1 study of MT-0169 based on previously disclosed cardiac adverse events noted in two patients dosed at 50 mcg/kg that prompted the dose reduction to 5 mcg/kg last year.

BridgeBio Pharma, Inc. today announced that on March 7, 2023, the compensation committee of BridgeBio’s board of directors granted five new employees restricted stock units for an aggregate of 25,900 shares of the Company’s common stock.

Select Medical Holdings Corporation (“Select Medical”) (NYSE: SEM), will release the financial results for its first quarter ended March 31, 2023 on Thursday, May 4, 2023 after the market closes.

Arcutis Biotherapeutics, Inc. today reported the grant of an aggregate of 83,250 restricted stock units of Arcutis’ common stock as well as options to purchase an aggregate of 33,000 shares of Arcutis’ common stock to 10 newly hired employees.